Bearishness Around Pfizer Gilead Sparks Opportunity
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
A strong index level often signals robust momentum and potential persistence. Interpret carefully to adjust positions and risk exposure.
24,405 articlesWall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
Alphabet unveils a clear AI cost advantage from its own silicon and models, triggering renewed investor interest as e...
Apple accelerates its cash-return program with a fresh buyback authorization and a dividend bump, underscoring a disc...
Myro (MYRO) faces a high-volatility path as traders eye 2025 to 2030 targets. This report lays out the price scenario...
A new JPMORGAN CHASE INSTITUTE study shows american small business bills tripled in 2025 as tariff costs surged, pres...
The U.S. economy posted 2.2% growth for 2025, a modest slowdown from 2024, with late-year softness in Q4. Consumers a...
Ownwell secures a $50M Series B to broaden its AI-driven tax-appeals platform and roll out a nationwide packet for ho...
Hims & Hers Health fell after guiding Q1 2026 revenue below expectations, citing a $65 million headwind from regulato...
A diversified ETF bundles 38 clean-energy names into a single exposure, aiming for long-term growth as policy timelin...
Netflix has opted not to top Paramount's offer, prompting Warner Bros. Discovery to align with Paramount. The move co...
U.S. equities ended February with sharp moves as a private-credit risk cycle and AI-driven volatility rattled investo...
The Pentagon’s fight with Anthropic has become a landmark test of how the U.S. will regulate powerful AI. Markets and...